- This topic has 1 reply, 2 voices, and was last updated 1 week, 4 days ago by
.
-
Posts
-
-
-
Warfarin is an oral anticoagulant used to prevent and treat blood clots in conditions such as deep vein thrombosis (DVT), pulmonary embolism (PE), and atrial fibrillation. It is also used in patients with certain mechanical heart valves. Although warfarin is effective, the appropriate dose varies considerably between individuals. Pharmacogenetic testing can help predict a patient’s initial warfarin dose by identifying genetic variations that influence drug metabolism and sensitivity.
Two major genes involved in warfarin dosing are CYP2C9 and VKORC1. The CYP2C9 gene encodes an enzyme responsible for metabolising the more potent S-warfarin enantiomer. Certain variants, including CYP2C9 *2 and *3, reduce enzyme activity, resulting in slower drug clearance and an increased risk of excessive anticoagulation and bleeding. The VKORC1 gene encodes vitamin K epoxide reductase, the target of warfarin. Variants in its regulatory region can alter gene expression and influence how sensitive a patient is to warfarin. Patients with certain VKORC1 variants may require lower doses, whereas others may require higher doses.
Additional factors, including age, body weight, liver function, dietary vitamin K intake, interacting medications, smoking status, and clinical indication, also influence dose requirements. Therefore, genetic information is often combined with clinical variables in validated warfarin-dosing algorithms to estimate an appropriate starting dose.
Pharmacogenetic testing may be particularly useful when initiating therapy in selected patients, especially when genetic results are available before treatment begins. It can help clinicians avoid excessive initial dosing in genetically sensitive individuals and potentially reduce the risk of adverse events. However, the clinical benefit varies according to the patient population, availability of genetic results, and quality of anticoagulation management.
Importantly, genetic testing cannot determine the exact dose required by every patient. It provides an estimate or starting-dose recommendation rather than a permanent prescription. The final dose must be individualised according to the patient’s response, measured through regular International Normalized Ratio (INR) testing.
-
- You must be logged in to reply to this topic.